Raj Airey

Cytovation AS is a Norwegian clinical stage immune-oncology company that focuses on developing Cypep-1, a first-in-class immunotherapy that targets the cell membrane of tumor cells. The company is a spin-off from the University of Bergen and is headquartered in Bergen, Norway. Cypep-1 has a unique mechanism of action that eliminates cancer cells by forming pores in the plasma membrane, releasing antigens to the immune system, promoting an inflammatory microenvironment, and inducing a tumor-specific immune response by in situ vaccination. Cytovation develops treatments for solid tumors in oncology and rare diseases, building on over 15 years of cutting-edge research. The CEO is Lars Prestegarden, and the company was founded by Rolf Bjerkvig, Per Eystein, and Stein Christian Mohn.

SOM Innovation Biotech SA engages in the discovery and development of new indications for known drugs. Its pipeline consists of repositioned compounds for the treatment of amyloidosis, huntington's disease, hyperplasia, glioblastoma, and alzheimer's disease. The company was founded by Raul Insa Boronat and Ignasi Belda Reig on December 30, 2009 and is headquartered in Barcelona, Spain.